Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing ...
Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...
The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback